Trial Profile
Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Fulranumab (Primary)
- Indications Musculoskeletal pain
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database record. (2016-09-15)
- 13 Jun 2019 this trial has been completed in UK.
- 23 May 2016 Planned End Date changed from 1 Feb 2018 to 1 Sep 2016.